View in EDS

LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.

Saved in:
Bibliographic Details
Title: LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Authors: Yeboah M; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Papagregoriou C; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Jones DC; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom., Chan HTC; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Hu G; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., McPartlan JS; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Schiött T; BioInvent International AB, Lund, Sweden., Mattson U; BioInvent International AB, Lund, Sweden., Mockridge CI; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Tornberg UC; BioInvent International AB, Lund, Sweden., Hambe B; BioInvent International AB, Lund, Sweden., Ljungars A; BioInvent International AB, Lund, Sweden., Mattsson M; BioInvent International AB, Lund, Sweden., Tews I; Institute for Life Sciences and.; Biological Sciences, University of Southampton, Southampton, United Kingdom., Glennie MJ; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Thirdborough SM; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Trowsdale J; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom., Frendeus B; BioInvent International AB, Lund, Sweden., Chen J; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Cragg MS; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Roghanian A; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Source: JCI insight [JCI Insight] 2020 Sep 01; Vol. 5 (18). Date of Electronic Publication: 2020 Sep 01.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32870822
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yeboah+M%22">Yeboah M</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Papagregoriou+C%22">Papagregoriou C</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Jones+DC%22">Jones DC</searchLink>; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Chan+HTC%22">Chan HTC</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hu+G%22">Hu G</searchLink>; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22McPartlan+JS%22">McPartlan JS</searchLink>; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Schiött+T%22">Schiött T</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Mattson+U%22">Mattson U</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Mockridge+CI%22">Mockridge CI</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Tornberg+UC%22">Tornberg UC</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Hambe+B%22">Hambe B</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Ljungars+A%22">Ljungars A</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Mattsson+M%22">Mattsson M</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Tews+I%22">Tews I</searchLink>; Institute for Life Sciences and.; Biological Sciences, University of Southampton, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Glennie+MJ%22">Glennie MJ</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Thirdborough+SM%22">Thirdborough SM</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Trowsdale+J%22">Trowsdale J</searchLink>; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Frendeus+B%22">Frendeus B</searchLink>; BioInvent International AB, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Cragg+MS%22">Cragg MS</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Roghanian+A%22">Roghanian A</searchLink>; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101676073%22">JCI insight</searchLink> [JCI Insight] 2020 Sep 01; Vol. 5 (18). <i>Date of Electronic Publication: </i>2020 Sep 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101676073 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2379-3708 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223793708%22">23793708 </searchLink><i>NLM ISO Abbreviation: </i>JCI Insight <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32870822
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1172/jci.insight.141593
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yeboah M
      – PersonEntity:
          Name:
            NameFull: Papagregoriou C
      – PersonEntity:
          Name:
            NameFull: Jones DC
      – PersonEntity:
          Name:
            NameFull: Chan HTC
      – PersonEntity:
          Name:
            NameFull: Hu G
      – PersonEntity:
          Name:
            NameFull: McPartlan JS
      – PersonEntity:
          Name:
            NameFull: Schiött T
      – PersonEntity:
          Name:
            NameFull: Mattson U
      – PersonEntity:
          Name:
            NameFull: Mockridge CI
      – PersonEntity:
          Name:
            NameFull: Tornberg UC
      – PersonEntity:
          Name:
            NameFull: Hambe B
      – PersonEntity:
          Name:
            NameFull: Ljungars A
      – PersonEntity:
          Name:
            NameFull: Mattsson M
      – PersonEntity:
          Name:
            NameFull: Tews I
      – PersonEntity:
          Name:
            NameFull: Glennie MJ
      – PersonEntity:
          Name:
            NameFull: Thirdborough SM
      – PersonEntity:
          Name:
            NameFull: Trowsdale J
      – PersonEntity:
          Name:
            NameFull: Frendeus B
      – PersonEntity:
          Name:
            NameFull: Chen J
      – PersonEntity:
          Name:
            NameFull: Cragg MS
      – PersonEntity:
          Name:
            NameFull: Roghanian A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2020 Sep 01
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 2379-3708
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 18
          Titles:
            – TitleFull: JCI insight
              Type: main
ResultId 1